Clone 13-infected Aedes aegypti salivary components inhibit Rift Valley fever virus pathogenicity

Alain Le Coupanec; Divya Babin; Michèle Bouloy; Valérie Choumet

doi:10.1016/j.micinf.2014.01.008

Clone 13-infected Aedes aegypti salivary components inhibit Rift Valley fever virus pathogenicity

Microbes Infect. 2014 May;16(5):439-44. doi: 10.1016/j.micinf.2014.01.008. Epub 2014 Feb 13.

Authors

Alain Le Coupanec¹, Divya Babin¹, Michèle Bouloy¹, Valérie Choumet²

Affiliations

¹ Unité de Génétique Moléculaire des Bunyavirus, Institut Pasteur, 25 rue du Dr Roux, Paris, France.
² Unité de Génétique Moléculaire des Bunyavirus, Institut Pasteur, 25 rue du Dr Roux, Paris, France; Unité Interactions Moléculaires Flavivirus-Hôtes, Institut Pasteur, 25 rue du Dr Roux, Paris, France. Electronic address: vchoumet@pasteur.fr.

PMID: 24530502
DOI: 10.1016/j.micinf.2014.01.008

Abstract

Rift Valley fever virus (RVFV) continues to cause large outbreaks among humans and domestic animals in Africa. RVFV Clone 13, a naturally attenuated clone, is a promising vaccine which was used during the 2009-2010 outbreak in South Africa and played a key role in the control of the disease. In this work, we infected Aedes aegypti mosquitoes with RVFV Clone 13 and prepared salivary gland extracts (SGE). C57BL/6-NRJ male mice were infected with a mixture of SGE infected by Clone 13 and the ZH548 RVFV strain. With the injection of increasing doses of Clone 13-infected SGE, all mice were protected. Our results suggest Clone 13 infected SGE contain unique antiviral components able to counteract the replication of RVFV when injected into vertebrates.

Keywords: Aedes aegypti; Arbovirus; Clone 13; Pathogenicity; Rift Valley fever virus; Salivary gland.

MeSH terms

Aedes / immunology
Aedes / virology*
Animals
Female
Male
Mice, Inbred C57BL
Rift Valley fever virus / immunology*
Saliva / immunology
Saliva / virology
Vaccines, Attenuated / immunology
Viral Vaccines / immunology*

Substances

Vaccines, Attenuated
Viral Vaccines